Q-omics provides the consensus-scored CYCSP34 profile across patient tissues and cancer cell-line models. CYCSP34 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYCSP34 is differentially expressed in 8, with the highest sampling consensus in STAD. Additionally, CYCSP34 RNA expression shows 19,618 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, STAD, and UVM as cancer lineages where CYCSP34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYCSP34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYCSP34 survival associations across molecular data types. CYCSP34 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYCSP34 RNA expression–survival associations across cancer types. High CYCSP34 expression shows unfavorable associations in KIRC, UVM and LIHC, but favorable associations in UCEC, THYM and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYCSP34 RNA expression.
This table summarizes CYCSP34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYCSP34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYCSP34 shows lower tumor expression in THCA and LUSC and higher tumor expression in STAD, COAD, LIHC and CHOL. The STAD box plot shows higher CYCSP34 RNA expression in tumor versus normal tissue (log2 FC = +0.670, t-test p < 0.001).
This table shows molecular features associated with CYCSP34 in patient tissues and cancer cell lines. In patient samples, CYCSP34 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
